JCT  Vol.3 No.5 , October 2012
Markers for Diagnosis and Progression in Bladder Cancer
Abstract: Bladder cancer is a common disease that is often detected late and has a high rate of recurrence and progression. The current standard of care for the primary detection and follow-up of NMIBC consists of urethro-cystoscopy associated with cytology. However, several clinical risk factors have been claimed to predict recurrence and progression, these factors have a predictive value on a population basis, but no parameter has been found that reliably predicts how an individual patient’s tumor will behave. In the last years many markers have been described in order to decrease the number of cystoscopies and try to provide individualized risk-stratified decision-making. We have focused our review in tumor markers for primary diagnosis, surveillance of non-muscle-invasive bladder cancer, and predicting progression to muscle-invasive disease. After our review, we can conclude that to the date no non-invasive biomarker has proven to be sensitive and specific enough to replace cystoscopy, neither in the diagnosis nor in the follow-up. On the other hand, promising results have been reported of potential biomarkers for predicting recurrence, early progression and poor response to BCG, new studies should be promoted to validate these results and make possible to incorporate markers as a new tool in clinical guidelines.
Cite this paper: J. Gaya, J. Palou, O. Rodríguez and H. Villavicencio, "Markers for Diagnosis and Progression in Bladder Cancer," Journal of Cancer Therapy, Vol. 3 No. 5, 2012, pp. 482-486. doi: 10.4236/jct.2012.35062.

[1]   D. M. Parkin, F. Bray, J. Gerlay, et al., “Global Cancer Statistics, 2002,” CA: A Cancer Journal for Clinicians, Vol. 55, No. 2, 2005, pp. 74-108. doi:10.3322/canjclin.55.2.74

[2]   M. Grasso, “Bladder Cancer: A Major Public Health Issue,” European Urology Supplements, Vol. 7, No. 7, 2008, pp. 510-515. doi:10.1016/j.eursup.2008.04.001

[3]   M. Babjuk, W. Oosterlinck, R. Sylvester, E. Kaasinen, A. Bohle, J. Palou-Redorta and M. Rouprêt, “European Guidelines on Non-Muscle Invasive Bladder Cancer TaT1 and CIS,” European Urology, Vol. 59, No. 6, 2011, pp. 997-1008.

[4]   R. J. Sylvester, A. P. Van der Meijden, W. Oosterlinck, et al., “Predicting Recurrence and Progression in Individual Patients with Stage TaT1 Bladder Cancer Using EORTC Risk Tables: A Combined Analysis of 2596 Patients from Seven EORTC Trials,” European Urology, Vol. 49, No. 3, 2006, pp. 466-477. doi:10.1016/j.eururo.2005.12.031

[5]   R. J. Sylvester, A. Van der Meijden, D. L. Lamm, et al., “Intravesical Bacillus Calmette-Guerin Reduces the Risk of Progression in Patients with Superficial Bladder Cancer: A Meta-Analysis of the Published Results of Randomized Clinical Trials,” The Journal of urology, Vol. 168, No. 5, 2002, pp. 1964-1970.doi:10.1016/S0022-5347(05)64273-5

[6]   J. Huguet, J. M. Gaya, S. Sabate, et al., “Radical Cystectomy in Patients with Non-Muscle Invasive Bladder Cancer Who Fail BCG Therapy,” Actas Urológicas Espanolas, Vol. 34, No. 1, 2010, pp. 63-70. doi:10.1016/S0210-4806(10)70011-5

[7]   C. L. Amling, J. B. Thrasher, H. A. Frazier, et al., “Radical Cystectomy for Stages Ta, Tis and T1 Transitional Cell Carcinoma of the Bladder,” The Journal of Urology, Vol. 151, No. 1, 1994, pp. 31-36.

[8]   M. Brausi, J. A. Witjes, D. Lamm, R. Persad, J. Palou, M. Colombel, R. Buckley, M. Soloway, H. Akaza and A. Bohle, “A Review of Current Guidelines and Best Practice Recommendations For the Management of Nonmuscle Invasive Bladder Cancer by the International Bladder Cancer Group,” European Urology, Vol. 186, No. 6, 2011, pp. 2158-2167.

[9]   F. Millan-Rodriguez, G. Chechile-Toniolo, J. Salvador-Bayarri, et al., “Multivariate Analysis of the Prognostic Factors of Primary Superficial Bladder Cancer,” The Journal of Urology, Vol. 163, No. 1, 2000, pp. 73-78.doi:10.1016/S0022-5347(05)67975-X

[10]   J. Palou, J. M. Gaya, R. Sylvester, et al., “Prognostic Factors for Recurrence and Progression in T1G3 Bladder Cancer Treated with BCG: CIS in the Prostatic Urethra and Gender,” European Urology Supplements, Vol. 8, No. 4, 2009, p. 285. doi:10.1016/S1569-9056(09)60653-9

[11]   Y. Lotan, S. F. Shariat, B. J. Schmitz-Drager, et al., “Considerations on Implementing Diagnostic Markers into Clinical Decision Making in Bladder Cancer,” Urologic Oncology: Seminars and Original Investigations, Vol. 28, No. 4, 2010, pp. 441-448.

[12]   Y. Lotan, S. F. Shariat, et al., (NMP22 Study Group), “Impact of Risk Factors on the Performance of the Nuclear matrix Proteína 22 Point-of-Care-Test for Bladder Cancer Detection,” BJU International, Vol. 101, No. 11, 2008, pp. 1362-1367.doi:10.1111/j.1464-410X.2008.07473.x

[13]   V. B. Lobeshwar, T. Habuchi, H. B. Grossman, et al., “Bladder Tumor Markers Consensus Panel,” Urology, Vol. 66, Suppl. 6, 2005, pp. 35-63.

[14]   B. Van Rhijin, H. Van der Poel, T. Van der Kwast, et al., “Citology and Urinary Markers for the Diagnosis of Bladder Cancer,” European Urology Supplements, Vol. 8, No. 7, 2009, pp. 536-541.doi:10.1016/j.eursup.2009.06.008

[15]   M. Babjuk, V. Soukup, M. Pesl, et al., “Urinary Cytology and Quantitative BTA and UBC Tests in Surveillance of Patients with pTapT1 Bladder Urothelial Carcinoma,” Urology, Vol. 71, No. 4, 2008, pp. 718-722.doi:10.1016/j.urology.2007.12.021

[16]   M. P. Raitanen, “The Role of BTA stat Test in Follow-Up of Patients with Bladder Cancer: Results from Finn-Bladder Studies,” World Journal of Urology, Vol. 26, No. 1, 2008, pp. 45-50. doi:10.1007/s00345-007-0230-3

[17]   Y. Lotan, S. F. Shariat and N. S. Grp, “Impact of Risk Factors on the Performance of the Nuclear Matrix Protein 22 Point-of-Care Test for Bladder Cancer Detection,” BJU International, Vol. 101, No. 11, 2008, pp. 1362-1367. doi:10.1111/j.1464-410X.2008.07473.x

[18]   C. T. Nguyen and J. S. Jones, “Defining the Role of NMP22 in Bladder Cancer Surveillance,” World Journal of Urology, Vol. 26, No. 1, 2008, pp. 51-58. doi:10.1007/s00345-007-0226-z

[19]   B. J. Schlomer, R. Ho, A. Sagalowsky, et al., “Prospective Validation of the Clinical Usefulness of Reflex Fluorescence in Situ Hybridization Assay in Patients with Atypical Cytology for the Detection of Urothelial Carcinoma of the Bladder,” The Journal of Urology, Vol. 183, No. 1, 2010, pp. 62-67.

[20]   J. Bergman, R. C. Reznichek and J. Rajfer, “Surveillance of Patients with Bladder Carcinoma Using Fluorescent insitu Hybridization on Bladder Washings,” BJU Inter- national, Vol. 101, No. 1, 2008, pp. 26-29.

[21]   G. Mowatt, S. Zhu, M. Kilonzo, et al., “Systematic Review of the Clinical Effectiveness and Cost-Effectiveness of Photodynamic Diagnosis and Urine Biomarkers (FISH, ImmunoCyt, NMP22) and Cytology for the Detection and Follow-Up of Bladder Cancer,” Health Technol Assess, Vol. 14, No. 4, 2010, pp. 1-331.

[22]   B. J. Schmitz-Drager, B. Beiche, L. A. Tirsar, et al., “Immunocytology in the Assessment of Patients with Asymptomatic Microhaematuria,” European Urology, Vol. 51, No. 6, 2007, pp. 1582-1588. doi:10.1016/j.eururo.2006.10.046

[23]   M. N. M. van der Aa, E. C. Zwarthoff, E. W. Steyerberg, et al., “Microsatellite Analysis of Voided-Urine Samples for Surveillance of Low-Grade Non-Muscle-Invasive Urothelial Carcinoma: Feasibility and Clinical Utility in a Prospective Multicenter Study (Cost-Effectiveness of Follow-Up of Urinary Bladder Cancer Trial [CEFUB]),” European Urology, Vol. 55, No. 3, 2009, pp. 659-667.doi:10.1016/j.eururo.2008.05.001

[24]   E. W. de Bekker-Grob, M. N. van der Aa, E. C. Zwarthoff, et al., “Non-Muscle-Invasive Bladder Cancer Surveillance for Which Cystoscopy is Partly Replaced by Microsatellite Analysis of Urine: A Cost-Effective Alternative?” BJU International, Vol. 104, No. 1, 2009, pp. 41-47. doi:10.1111/j.1464-410X.2008.08323.x

[25]   H. X. Li, M. Li, L. C. Li, et al., “Immunocyt and Cytokeratin 20 Immunochemistry as Adjunt Marker for Urine Cytologic Detection of Baldder Cancer: A Prospective Study,” Analytical and Quantitative Cytology and Histology, Vol. 32, No. 1, 2010, pp. 45-52.

[26]   F. Barbisan, A. Santinelli, R. Mazzucchelli, et al., “Strong Immunohistochemichal Expression of fibroblast Growth Factor Receptor 3 Superficial Staining Pattern of Cytokeratin 20, Low Proliferative Activity Define Those Papillary Neoplasms of Low Malignant Potencial That Do Not Recur,” Cancer, Vol. 112, No. 3, 2008, pp. 636-644.

[27]   G. Legrand, H. Soliman, F. Dubosq, et al., “Prevalence and Spectrum of Microsatellite Alterations in Nonmuscle Invasive Bladder Cancers,” American Journal of Cancer Research, Vol. 1, No. 5, 2011, pp. 595-603.

[28]   R. T. Bryan, S. A. Hussain, N. D. James, et al., “Molecular Pathway in Bladder Cancer. Part 1,” BJU Inter- national, Vol. 95, No. 4, 2005, pp. 485-490. doi:10.1111/j.1464-410X.2005.05325.x

[29]   R. T. Bryan, S. A. Hussain, N. D. James, et al., “Molecular Pathway in Bladder Cancer. Part 2,” BJU Inter- national, Vol. 95, No. 4, 2005, pp. 491-496 doi:10.1111/j.1464-410X.2005.05326.x

[30]   J. B. Jensen, P. P.Munksgard, C. M.Sorensen, et al., “High Expression of Karyopherin-x2 Defines Poor Prognosis in Non-Muscle-Invasive Bladder Cancer and in Patients with Invasive Bladder Cancer Undergoing Radical Cystectomy,” European Urology, Vol. 59, No. 5, 2011, pp. 841-848. doi:10.1016/j.eururo.2011.01.048

[31]   M. Yim, Y. Ha, I. Kim, et al., “HMOX1 is an Important Prognostic Indicator of Non-Muscle Invasive Bladder Cancer Recurrence and Progresión,” The Journal of Urology, Vol. 185, No. 2, 2011,pp. 701-705. doi:10.1016/j.juro.2010.09.081

[32]   Y. S. Ha, C. Yan, P. Jeong, et al., “GSTM1 Tissue Genotype as a Recurrence Predictor in Non-Muscle Invasive Bladder Cancer,” Journal of Korean Medical Science, Vol. 26, No. 2, 2011, pp. 231-236.doi:10.3346/jkms.2011.26.2.231

[33]   Y. S. Ha, C. Yan, M. Lym, et al., “GSTT1 as a Prognosticator for Recurrence and Progresión in Patients with Non-Muscle-Invasive Bladder Cancer,” Disease Markers, Vol. 29, No. 2, 2010, pp. 81-87.

[34]   W. T. Kim, S. J. Yon, C. Park, et al., “Identification of c16orf74 as a Marker of Progresión in Primary Non- Muscle Invasive Bladder Cancer,” PLoS One, Vol. 5, No. 12, 2010, p. e15260.

[35]   L. C. Kompier, I. Lurkin, M. N. M. van der Aa, et al., “FGFR3, HRAS,KRAS,NRAS and PIK3CA Mutations in Bladder Cancer and Their Potential as Biomarkers for Surveillance and Therapy,” PLoS One, Vol. 5, No. 11, 2010, p. e13821. doi:10.1371/journal.pone.0013821

[36]   O. Karni-Schmidt, M. Castillo-Martin, T. H. Shen, et al., “Distinct Expresión Profiles of p63 Variants Turing Urothelial Development and Bladder Cancer Progresión,” The American Journal of Pathology, Vol. 178, No. 3, 2011, pp. 1350-1360. doi:10.1016/j.ajpath.2010.11.061

[37]   A. Janane, F. Hajji, T. O. Ismail, et al., “Evaluation of HER2 Protein Overexpression in Non-Muscle-Invasive Bladder Cancer with Emphasis on Tumor Grade and Recurrence,” Actas Urológicas Espa?olas, Vol. 35, No. 4, 2011, pp. 189-194. doi:10.1016/S2173-5786(11)70048-8

[38]   J. Palou, F. Algaba, I. Vera, M. Sánchez-Carbayo, et al., “Protein Expression Patterns of Ezrin Are Predictors of Progresión in T1G3 Bladder Tumors Treated with Non- Maintenance Bacillus Calmette-Guérin,” European Urology, Vol. 56, No. 5, 2009, pp. 829-836. doi:10.1016/j.eururo.2008.09.062

[39]   M. Agundez, L. Grau, J. Palou, et al., “Evaluation of the Methylation Status of Tumor Supressor Genes for Pre- dicting Bacillus Calmette-Guérin Response in Patients with T1G3 High Risk Bladder Tumours,” European Urology, Vol. 60, No. 1, 2011, pp. 131-140. doi:10.1016/j.eururo.2011.04.020

[40]   B. George, R. H. Datar, L. Wu, et al., “p53 Gene and Proteína Status: The Role of p53 Alterations in Predicting Outcome in Patients with Bladder Cancer,” Journal of Clinical Oncology, Vol. 25, No. 34, 2007, pp. 5352-5358. doi:10.1200/JCO.2006.10.4125

[41]   A. S. Salinas-Sánchez, J. G. Lorenzo-Romero, J. M. Giménez-Bachs, et al., “Implications of p53 Gene Mutations on Patient Survival in Transicional Cell Carcinoma of the Bladder: A Long Term Study,” Urologic Oncology: Seminars and Original Investigations, Vol. 26, No. 6, 2008, pp. 620-626. doi:10.1016/j.urolonc.2007.07.011

[42]   R. T. Bryan, P. Zeegers, N. D. James, et al., “Biomarkers in Bladder Cancer,” BJU International, Vol. 57, No. 1, 2009, pp. 1-13. doi:10.1111/j.1464-410X.2009.08880.x

[43]   P. Mhawech-Fanceglia, G. Fischer, V. Jr. Alvarez, et al., “Predicting Outcome in Minimally Invasive (T1a and T1b) Urothelial Bladder Carcinoma Using a Panel of Biomarkers: A High Throughput Tissue Microarray Analisis,” BJU International, Vol. 100, No. 5, 2007, pp. 1182-1187.

[44]   A. W. Hitchings, M. Kumar, S. Jordan, et al., “Prediction of Progression in pTa and pT1 Bladder Carcinomas with p53,16 and pRb,” British Journal of Cancer, Vol. 91, No. 3, 2004, pp. 552-557. doi:10.1038/sj.bjc.6601954

[45]   K. Diamantopoulou, A. Lazaris, E. Mylona, et al., “Cycloxigenase-2 Protein Expression in Relation to Apoptotic Potential and Its Prognostic Significance in Bladder Urothelial Carcinoma,” Anticancer Research, Vol. 25, No. 6, 2005, pp. 4543-4549.